The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Insulin glargine
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Insulin prescriptions—particularly glargine (long-acting) and aspart (rapid-acting)—were the next strongest clinical predictors, suggesting that patients requiring both basal and rapid-acting insulin have more complex or less stable disease [81,82].”
From Machine learning-driven risk prediction for post-hospitalization diabetes case management: Integrating clinical and social determinants of health (2026) · cites this paper as [81]
Citations
Cites
Kurtzhals, P., Schäffer, L., Sørensen, A., Kristensen, C., Jonassen, I., Schmid, C., & Trüb, T. (2000) · Diabetes · doi:10.2337/diabetes.49.6.999 · Cited by 739
Continuous subcutaneous insulin infusion: an approach to achieving normoglycaemia.
Pickup, J. C., KEEN, H., PARSONS, J. A., & Alberti, K. G. M. M. (1978) · BMJ · doi:10.1136/bmj.1.6107.204 · Cited by 563
Smith, L. E. H., Shen, W., Perruzzi, C. A., Söker, S., Kinose, F., Xu, X., Robinson, G. S., Driver, S., Bischoff, J. E., Zhang, B., et al. (1999) · Nature Medicine · doi:10.1038/70963 · Cited by 555
Heinemann, L., Linkeschova, R., Rave, K., Hompesch, B., Sedlak, M., & Heise, T. (2000) · Diabetes Care · doi:10.2337/diacare.23.5.644 · Cited by 474
Ratner, R. E., Hirsch, I. B., Neifing, J. L., Garg, S. K., Mecca, T. E., & Wilson, C. A. (2000) · Diabetes Care · doi:10.2337/diacare.23.5.639 · Cited by 455
Insulin analogues and their potential in the management of diabetes mellitus
Bolli, G. B., DiMarchi, R. D., Park, G. D., Pramming, S., & Koivisto, V. A. (1999) · Diabetologia · doi:10.1007/s001250051286 · Cited by 351
Self-citationInadequate suspension of neutral protamine Hagendorn (NPH) insulin in pens
Jehle, P. M., Micheler, C., Jehle, D. R., Breitig, D., & Boehm, B. O. (1999) · The Lancet · doi:10.1016/s0140-6736(98)12459-5 · Cited by 185
Slieker, L. J., Brooke, G. S., DiMarchi, R. D., Flora, D. B., Green, L. K., Hoffmann, J. A., Long, H. B., Fan, L., Shields, J. E., Sundell, K. L., et al. (1997) · Diabetologia · doi:10.1007/s001250051402 · Cited by 138
Berti, L., Kellerer, M., Bossenmaier, B., Seffer, E., Seipke, G., & Häring, H.-U. (1998) · Hormone and Metabolic Research · doi:10.1055/s-2007-978849 · Cited by 93
Diabetes: Current Perspectives
Betteridge, D. J. (1999) · Cited by 22
Research works printed but not linked: 4
- Lepore, 1999, Pharmacokinetics and dynamics of s. c. injection of the long-acting insulin glargine (HOE901) in T1DM, Diabetes, 48, A97
- Pieber, 1999, Efficacy and safety of HOE 901 in patients with type 1 diabetes: a four-week randomised, NPH insulin-controlled trial, Diabetes, 47, A62
- Yki-Järvinen, 2000, Study Group – HOE 901/3002. Comparison of insulin glargine (HOE901) vs NPH during 1 year of insulin combination therapy in Type 2 diabetes, Diabetes, 49, A130
- Bolli, 1999, Rationale for using combinations of short-acting insulin analogue and NPH insulins at mealtime in the treatment of Type 1 diabetes mellitus, J Ped Endocrinol Metab, 12, 737
Cited by
Sorted by citations
Type 1 diabetes: new perspectives on disease pathogenesis and treatment
Atkinson, M. A., & Eisenbarth, G. S. (2001) · The Lancet · doi:10.1016/s0140-6736(01)05415-0 · Cited by 1,491
Riddle (2003) · doi:10.2337/diacare.26.11.3080 · Cited by 1,479
The Diagnosis and Management of Lipodystrophy Syndromes: A Multi-Society Practice Guideline
Brown, R. J., Araújo‐Vilar, D., Cheung, P. T., Dunger, D. B., Garg, A., Jack, M., Mungai, L., Oral, E. A., Patni, N., Rother, K. I., et al. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-2466 · Cited by 540
ACOG Practice Bulletin No. 201: Pregestational Diabetes Mellitus
(2018) · Obstetrics and Gynecology · doi:10.1097/aog.0000000000002960 · Cited by 488
The Mechanism of Protraction of Insulin Detemir, a Long-Acting, Acylated Analog of Human Insulin
Havelund, S., Plum, A., Ribel, U., Jonassen, I., Vølund, A., Markussen, J., & Kurtzhals, P. (2004) · Pharmaceutical Research · doi:10.1023/b:pham.0000036926.54824.37 · Cited by 431
Metadata
- Authors
- Bolli, G. B., & Owens, D. R.
- Affiliations
- University of Perugia (IT)
- University of Wales (GB)
- Corresponding author
- Bolli, Geremia B
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2000-08
- Volume
- 356
- Issue
- 9228
- Pages
- 443-445
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W4243765000
- Cited by
- 186
- References
- 10
- Citations by year
- 2026: 7 · 2025: 5 · 2024: 3 · 2023: 4 · 2022: 8 · 2021: 8 · 2020: 1 · 2019: 4 · 2018: 10 · 2017: 6 · 2016: 7 · 2015: 7 · 2014: 3 · 2013: 8 · 2012: 6
- FWCI
- 8.07
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Lancet (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- insulin glargine, long-acting insulin analogues, basal insulin, type 1 diabetes, type 2 diabetes, drug approval, drug safety, insulin therapy
- MeSH terms
- Insulin Glargine, Blood Glucose, Diabetes Mellitus, Humans, Hypoglycemic Agents, Insulin, Insulin, Long-Acting
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
